Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-18

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. Anlotinib is a novel tyrosine kinase inhibitor targeting both at VEGFR-2, -3 and PDGFRA and PDGFRB with high affinity, which also showed broad antitumor activity against EGFR and so on. Thus this multicenter, two-armed phase II trial of PKUPH-sarcoma 05 intended to investigate the efficacy and safety of anlotinib versus imatinib on advanced chordoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Imatinib in Chordoma

NCT00150072

Chordoma

COMPLETED PHASE2

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

NCT01742299

GIST and CML

ACTIVE_NOT_RECRUITING PHASE4

Imatinib in Adult Patients With Metastatic Ocular Melanoma

NCT00421317

Melanoma

TERMINATED PHASE2

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

NCT00427583

Malignant Peripheral Nerve Sheath Tumors

TERMINATED PHASE2/PHASE3

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

NCT00940563

Advanced Gastrointestinal Stromal Tumors

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Effect of Drugs Quality of Life Chordoma Advanced Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: anlotinib arm

anlotinib was given at a fixed dose of 12mg D1-14 every 21 days

Group Type EXPERIMENTAL

Anlotinib Hydrochloride

Intervention Type DRUG

anlotinib was given at a fixed dose of 12mg D1-14 every 21 days

Arm B: imatinib arm

Imatinib was given at dose of 400 mg twice daily continuously

Group Type ACTIVE_COMPARATOR

Anlotinib Hydrochloride

Intervention Type DRUG

anlotinib was given at a fixed dose of 12mg D1-14 every 21 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anlotinib Hydrochloride

anlotinib was given at a fixed dose of 12mg D1-14 every 21 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years and older;
* histologically proven metastatic or locally advanced chordoma, reviewed by the Pathology Committee of Peking University People's Hospital;
* not amenable to curative-intent surgery;
* measurable with computed tomography scan or magnetic resonance imaging, per RECIST, version 1.1.

Exclusion Criteria

* Eastern Cooperative Oncology Group (ECOG)30 performance status more than 2 ;
* life expectancy less than 12 weeks;
* with severe or uncontrolled medical disorders (≥grade 2 of Common Terminology Criteria for Adverse Events version 4.03 \[CTCAE version 4.03\]) that could jeopardise the outcomes of the study, for example, cardiac clinical symptom or disease with LVEF (left ventricular ejection fraction) \<50%, hypertension that could not be well controlled through antihypertensive drugs and so on;
* weight loss of 20% or more before illness;
* brain or leptomeningeal metastasis;
* surgical procedure or radiotherapy within 4 weeks of enrollment;
* active gastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation;
* proteinuria or hematuria;
* denutrition with albuminemia less than 25 g/L;
* pregnant or breastfeeding status;
* other malignancy, positive HBV/HCV/HIV serology;
* known allergy to the experimental agents;
* had ever used anti-angiogenesis TKIs.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No